177 related articles for article (PubMed ID: 36823043)
21. KDM6A promotes hepatocellular carcinoma progression and dictates lenvatinib efficacy by upregulating FGFR4 expression.
Guo W; Li S; Qian Y; Li L; Wang F; Tong Y; Li Q; Zhu Z; Gao WQ; Liu Y
Clin Transl Med; 2023 Oct; 13(10):e1452. PubMed ID: 37846441
[TBL] [Abstract][Full Text] [Related]
22. Glycochenodeoxycholate promotes hepatocellular carcinoma invasion and migration by AMPK/mTOR dependent autophagy activation.
Gao L; Lv G; Li R; Liu WT; Zong C; Ye F; Li XY; Yang X; Jiang JH; Hou XJ; Jing YY; Han ZP; Wei LX
Cancer Lett; 2019 Jul; 454():215-223. PubMed ID: 30980867
[TBL] [Abstract][Full Text] [Related]
23. Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo.
Wu CH; Hsu FT; Chao TL; Lee YH; Kuo YC
Biomed Pharmacother; 2022 Jan; 145():112437. PubMed ID: 34864311
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
25. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
26. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib.
Zheng Y; Huang C; Lu L; Yu K; Zhao J; Chen M; Liu L; Sun Q; Lin Z; Zheng J; Chen J; Zhang J
J Hematol Oncol; 2021 Jan; 14(1):16. PubMed ID: 33446239
[TBL] [Abstract][Full Text] [Related]
27. Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy.
Li J; Wu PW; Zhou Y; Dai B; Zhang PF; Zhang YH; Liu Y; Shi XL
Cell Death Dis; 2018 Feb; 9(2):225. PubMed ID: 29445087
[TBL] [Abstract][Full Text] [Related]
28. Naa20, the catalytic subunit of NatB complex, contributes to hepatocellular carcinoma by regulating the LKB1-AMPK-mTOR axis.
Jung TY; Ryu JE; Jang MM; Lee SY; Jin GR; Kim CW; Lee CY; Kim H; Kim E; Park S; Lee S; Lee C; Kim W; Kim T; Lee SY; Ju BG; Kim HS
Exp Mol Med; 2020 Nov; 52(11):1831-1844. PubMed ID: 33219302
[TBL] [Abstract][Full Text] [Related]
29. NR0B1 augments sorafenib resistance in hepatocellular carcinoma through promoting autophagy and inhibiting apoptosis.
Tan XL; Wang Z; Liao S; Yi M; Tao D; Zhang X; Leng X; Shi J; Xie S; Yang Y; Liu YQ
Cancer Sci; 2024 Feb; 115(2):465-476. PubMed ID: 37991109
[TBL] [Abstract][Full Text] [Related]
30. Sirolimus increases the anti-cancer effect of Huai Er by regulating hypoxia inducible factor-1α-mediated glycolysis in hepatocellular carcinoma.
Zhou L; Zhao Y; Pan LC; Wang J; Shi XJ; Du GS; He Q
World J Gastroenterol; 2022 Aug; 28(32):4600-4619. PubMed ID: 36157928
[TBL] [Abstract][Full Text] [Related]
31. NOD2 inhibits tumorigenesis and increases chemosensitivity of hepatocellular carcinoma by targeting AMPK pathway.
Ma X; Qiu Y; Sun Y; Zhu L; Zhao Y; Li T; Lin Y; Ma D; Qin Z; Sun C; Han L
Cell Death Dis; 2020 Mar; 11(3):174. PubMed ID: 32144252
[TBL] [Abstract][Full Text] [Related]
32. ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma.
Myojin Y; Kodama T; Maesaka K; Motooka D; Sato Y; Tanaka S; Abe Y; Ohkawa K; Mita E; Hayashi Y; Hikita H; Sakamori R; Tatsumi T; Taguchi A; Eguchi H; Takehara T
Clin Cancer Res; 2021 Feb; 27(4):1150-1161. PubMed ID: 33288659
[TBL] [Abstract][Full Text] [Related]
33. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.
Vara D; Salazar M; Olea-Herrero N; Guzmán M; Velasco G; Díaz-Laviada I
Cell Death Differ; 2011 Jul; 18(7):1099-111. PubMed ID: 21475304
[TBL] [Abstract][Full Text] [Related]
34. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways.
Wang J; Yu H; Dong W; Zhang C; Hu M; Ma W; Jiang X; Li H; Yang P; Xiang D
Gastroenterology; 2023 May; 164(6):990-1005. PubMed ID: 36764493
[TBL] [Abstract][Full Text] [Related]
35.
Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
37. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
[TBL] [Abstract][Full Text] [Related]
38. BCLB, methylated in hepatocellular carcinoma, is a starvation stress sensor that induces apoptosis and autophagy through the AMPK-mTOR signaling cascade.
Liu X; Hu X; Kuang Y; Yan P; Li L; Li C; Tao Q; Cai X
Cancer Lett; 2017 Jun; 395():63-71. PubMed ID: 28259820
[TBL] [Abstract][Full Text] [Related]
39. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells.
You Y; Zheng Q; Dong Y; Xie X; Wang Y; Wu S; Zhang L; Wang Y; Xue T; Wang Z; Chen R; Wang Y; Cui J; Ren Z
Oncotarget; 2016 May; 7(22):32221-31. PubMed ID: 27050147
[TBL] [Abstract][Full Text] [Related]
40. Hepatocellular carcinoma cells loss lenvatinib efficacy in vitro through autophagy and hypoxia response-derived neuropilin-1 degradation.
Fernández-Palanca P; Payo-Serafín T; San-Miguel B; Méndez-Blanco C; Tuñón MJ; González-Gallego J; Mauriz JL
Acta Pharmacol Sin; 2023 May; 44(5):1066-1082. PubMed ID: 36376373
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
